Biopharmaceutical manufacturer
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
MMM - Medicare/Medicaid HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
HAGGERTY POLICY SOLUTIONS
121 S Hudson St, Arlington, VA, 22204, US
JEANNE HAGGERTY JEANNE HAGGERTY